RenovoRx - Public Comps and Valuation Multiples

RenovoRx Overview

About RenovoRx

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.

Founded

2012

HQ

Employees

Website

renovorx.com

Sectors

Drug Development & Therapeutics
Drug Delivery Systems
BioTech

Financials

LTM Revenue $0.9M

Last FY EBITDA -$11.0M

EV

$34.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

RenovoRx Financials

As of August 2025, RenovoRx reported last 12-month revenue of $0.9M.

In the same period, RenovoRx generated $0.5M in LTM gross profit and -$10.5M in net income.

See RenovoRx valuation multiples based on analyst estimates

RenovoRx P&L

In the most recent fiscal year, RenovoRx reported revenue of $43K and EBITDA of -$11.0M.

RenovoRx expects next 12-month revenue of XXX and NTM EBITDA of XXX

See RenovoRx valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$0.9M	XXX	$43K	XXX	XXX	XXX
Gross Profit	$0.5M	XXX	$43K	XXX	XXX	XXX
Gross Margin	60%	XXX	100%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$11.0M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-25512%	XXX	XXX	XXX
EBIT	-$11.5M	XXX	-$11.0M	XXX	XXX	XXX
EBIT Margin	-1278%	XXX	-25512%	XXX	XXX	XXX
Net Profit	-$10.5M	XXX	-$8.8M	XXX	XXX	XXX
Net Margin	-1166%	XXX	-20498%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for RenovoRx including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $0.9M. In the most recent fiscal year, RenovoRx achieved $43K in revenue and -$11.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$0.9M	Analyst estimates available to subscribers	$43K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$0.5M	Analyst estimates available to subscribers	$43K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	60.2% gross margin	Analyst estimates available to subscribers	100.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$11.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-25511.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$11.5M	Analyst estimates available to subscribers	-$11.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1277.6% EBIT margin	Analyst estimates available to subscribers	-25511.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$10.5M	Analyst estimates available to subscribers	-$8.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1166.4% net profit margin	Analyst estimates available to subscribers	-20497.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for RenovoRx

This financial data table provides comprehensive performance metrics for RenovoRx, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

RenovoRx generated $0.9M in revenue over the last twelve months.
Gross profit for the last twelve months was $0.5M.
Net income over the last twelve months reached -$10.5M.

Fiscal Year Performance

In the most recent fiscal year, RenovoRx reported $43K in total revenue.
Fiscal year EBITDA was -$11.0M.
The company maintained a gross profit margin of 100.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -25511.6%.
Net profit margin reached -20497.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for RenovoRx. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

RenovoRx Stock Performance

RenovoRx has current market cap of $46.9M, and EV of $34.9M.

Market Cap Evolution

RenovoRx Stock Data

As of September 12, 2025, RenovoRx's stock price is $1.

See RenovoRx trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$34.9M	$46.9M	XXX	XXX	XXX	XXX	$-0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

RenovoRx Valuation Multiples

RenovoRx's trades at 810.5x EV/Revenue multiple, and -3.2x EV/EBITDA.

See valuation multiples for RenovoRx and 15K+ public comps

RenovoRx Financial Valuation Multiples

As of September 12, 2025, RenovoRx has market cap of $46.9M and EV of $34.9M.

Equity research analysts estimate RenovoRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

RenovoRx has a P/E ratio of -4.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$46.9M	XXX	$46.9M	XXX	XXX	XXX
EV (current)	$34.9M	XXX	$34.9M	XXX	XXX	XXX
EV/Revenue	38.7x	XXX	810.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-3.2x	XXX	XXX	XXX
EV/EBIT	-3.0x	XXX	-3.2x	XXX	XXX	XXX
EV/Gross Profit	64.2x	XXX	n/a	XXX	XXX	XXX
P/E	-4.5x	XXX	-5.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-3.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get RenovoRx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

RenovoRx Margins & Growth Rates

RenovoRx's last 12 month revenue growth is 349%

RenovoRx's revenue per employee in the last FY averaged $4K, while opex per employee averaged $1.1M for the same period.

RenovoRx's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RenovoRx's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for RenovoRx and other 15K+ public comps

RenovoRx Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	349%	XXX	1001%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-25512%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	-25163%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$4K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14012%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	25612%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial